Portal de investigación
Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Mussetti, Alberto
- Bento, Leyre
- Bastos-Oreiro, Mariana
- Rius Sansalvador, B.
- Albo, Carmen
- Bailen, Rebeca
- Barba, Pere
- Benzaquen, Ana
- Briones, Javier
- Caballero AC
- Campos, Antonio
- Espanol, Ignacio
- Ferra, Christelle
- López SG
- Gonzalez Sierra, Pedro Antonio
- Guerra LM
- Jiminez Ubieto, Ana Isabel
- Kwon, Mi
- Corral LL
- Lopez-Godino, Oriana
- Munoz, Maria Carmen Martinez
- Martinez-Cibrian, Nuria
- Gómez JM
- Perez-Ortega, Laura
- Orti, Guillermo
- Ortiz-Maldonado, Valentin
- Pascual, Maria-Jesus
- Perera, Maria
- Perez, Antonio
- Reguera JL
- Sanchez, Jose M.
- Torrent, Anna
- Yanez, Lucrecia
- Varela, Rosario
- Echechipia IC
- Caballero, Dolores
Grupos
Abstract
Anti-CD19 chimeric antigen receptor T cells (CART) has rapidly been adopted as the standard third-line therapy to treat aggressive B-cell lymphomas (ABCL) after failure of second-line therapy despite the lack of direct comparisons with allogeneic hematopoietic cell transplantation (alloHCT)-based strategies. Using the Grupo Espanol de Trasplante y Terapia Celular (GETH-TC) registry, we selected patients with the following characteristics: CART or alloHCT performed between 2016 and 2021; =18 years old; ABCL diagnosis; =2 lines of therapy; and either anti-CD19 CART or alloHCT as therapy at relapse. The analysis included a total of 316 (CART=215, alloHCT=101) patients. Median follow-up was 15 and 36 months for the CART and alloHCT cohorts, respectively. In the multivariate analysis, CART was confirmed to be similar to alloHCT for the primary study endpoint (progression-free survival) (hazard ratio [HR] 0.92, CI95%:0.56-1.51, p=0.75). Furthermore, when the analysis was limited to only patients with chemo-sensitive diseases (complete and partial response) at infusion (CART=26, alloHCT=93), no differences were reported (progression-free survival at month +18: 65% versus 55%, p=0.59). However, CART had lower non-relapse mortality (HR 0.34, 95% CI: 0.13-0.85, p=0.02). Given the lower toxicity and similar survival outcomes, these results suggest the use of CART before alloHCT.
© 2023. The Author(s), under exclusive licence to Springer Nature Limited.
Datos de la publicación
- ISSN/ISSNe:
- 0268-3369, 1476-5365
- Tipo:
- Article
- Páginas:
- 673-679
- PubMed:
- 36918682
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,998 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
BONE MARROW TRANSPLANTATION SPRINGERNATURE
Citas Recibidas en Web of Science: 12
Citas Recibidas en Scopus: 10
Documentos
- No hay documentos
Filiaciones
Keywords
- T-CELLS; RECOMMENDATIONS; OUTCOMES; BLOOD
Cita
Mussetti A,Bento L,Bastos M,Rius B,Albo C,Bailen R,Barba P,Benzaquen A,Briones J,Caballero AC,Campos A,Espanol I,Ferra C,López SG,Gonzalez PA,Guerra LM,HERNANI R,IACOBONI G,Jiminez AI,Kwon MI,Corral LL,Lopez O,Munoz MCM,Martinez N,Gómez JM,Perez L,Orti G,Ortiz V,Pascual M,Perera M,Perez A,Reguera JL,Sanchez JM,SANZ J,Torrent A,Yanez L,Varela R,Echechipia IC,Caballero D,SUREDA A. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era. Bone Marrow Transplant. 2023. 58. (6):p. 673-679. IF:4,500. (1).